Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.

Recruiting now

Conditions studied: Age-Related Macular Degeneration

In brief

The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.

Key facts

Study ID

NCT06899360

Run by

University of Udine

People needed

200

Starts

2024-10-01

Expected to finish

2029-10-01

Last updated by the study team

2025-03-27

Who can join

Age: 50 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age ≥ 50 years.
• confirmed diagnosis of AMD in at least one eye.
• follow-up scheduled according to standard clinical practice.

You may not qualify if…

• presence of other significant ocular conditions that could affect visual acuity.
• systemic conditions that make the patient unsuitable for long-term follow-up.

Where it is running

• Department of Ophthalmology — Udine, UD, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.